TherapeuticsMD (TXMD) Tops Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
TherapeuticsMD Announces Third Quarter 2018 Financial Results
November 7, 2018 4:05 PM EST-Strong early launch indicators for IMVEXXY-
-BIJUVA commercial launch planned for 2Q 2019-
-ANNOVERA commercial launch planned for 4Q 2019-
-Conference call scheduled for 4:30 p.m. ET today-
BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative womens healthcare company, today announced its clinical and corporate update for the quarter ended September 30, 2018.
We are extremely pleased with the momentum of the IMVEXXY launch, including our progress with negotiating commercial payer coverage, said Robert G. Finizio, Chief... More
